On October 10, 2019, Anderson, Niall A.; Campos, Sebastien; Butler, Sharon; Copley, Royston C. B.; Duncan, Ian; Harrison, Stephen; Le, Joelle; Maghames, Rosemary; Pastor-Garcia, Aleix; Pritchard, John M.; Rowedder, James E.; Smith, Claire E.; Thomas, Jack; Vitulli, Giovanni; Macdonald, Simon J. F. published an article.Formula: C15H22N2O3 The title of the article was Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis. And the article contained the following:
The heterodimeric transmembrane αv integrin receptors have recently emerged as potential targets for the treatment of idiopathic pulmonary fibrosis. Herein, we describe how subtle modifications of the central aromatic ring of a series of phenylbutyrate-based antagonists of the vitronectin receptors αvβ3 and αvβ5 significantly change the biol. activities against αvβ6 and αvβ8. This resulted in the discovery of a pan αv antagonist (compound 39, 4-40 nM for the integrin receptors named above) possessing excellent oral pharmacokinetic properties in rats (with a clearance of 7.6 mL/(min kg) and a bioavailability of 97%). The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Formula: C15H22N2O3
The Article related to phenylbutyrate derivative preparation oral integrin inhibitor idiopathic pulmonary fibrosis, Pharmacology: Structure-Activity and other aspects.Formula: C15H22N2O3
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem